Terlipressin

CAS No.: 14636-12-5

Terlipressin Chemical Structure

Molecular formula:C₅₂H₇₄N₁₆O₁₅S₂

Molecular weight: 1227.37 g·mol−1

Patent period: —

Dositive specifications:–

Injection :–

Oral tablets: —

Injection: —

Biological Activity

Terlipressin is a potent vasoconstrictor that acts via V1 receptors on arteriolar smooth muscle cells.

Chemical Properties

CAS NO.	14636-12-5
FORMULA	C₅₂H₇₄N₁₆O₁₅S₂
M.WT	1227.37
PURITY	_
SMILES	O=C([C@H](CSSC [C@@H](C(N[C@H] (C1=O)CC2=CC=C(O)C =C2)=O)NC(CNC (CNC(CN)=O)=O) =O)NC([C@@H] (NC([C@@H](NC ([C@](N1)([H])CC3 =CC=CC=C3)=O)CCC(N) =O)=O)CC(N)=O)=O) N(CCC4)[C@@H]4C(N[C@@H](CCCCN)C(NCC(N)=O) =O)=O
STORAGE	Store lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for 36 months. In solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Online Inquiry

Cardiovascular Disease

According to the terminal and pharmacy terminal data of Yao Rongyun Hospital, the scale of cardiovascular chemical drugs in China was close to 90 billion yuan in 2021, and the hospital terminals accounted for 74%.

Other Drug Peptide

Terzapitide NEW

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Semaglutide NEW

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.

Retatrutide NEW

Retatrutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR), glucose-dependent insulin- promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), developed for the treatment of obesity and related metabolic disorders.

Cagrilintide NEW

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acting as a nonselective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake.

Linaclotide NEW

Linaclotide is a potent and selective guanylate cyclase C agonist, developed for the treatment of constipation-type irritable bowel syndrome (IBS-C) and chronic constipation.

BESTBELL